Nordic Berries Put to the Test for Fighting Age-Related Cognitive Decline
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
Summary
Researchers at Aventure AB conducted a clinical trial to determine whether consuming a Nordic berry beverage — both as a single acute dose and as a daily 12-week regimen — could improve cognitive performance in adults without diagnosed cognitive disease. The trial also explored whether any cognitive benefits corresponded with measurable changes in metabolic markers. Nordic berries such as bilberries, lingonberries, and cloudberries are rich in polyphenols, particularly anthocyanins, which have shown promise in preclinical studies for supporting brain health and reducing neuroinflammation. This completed study adds to a growing body of human evidence on dietary interventions targeting age-related cognitive decline, a condition affecting millions globally and for which few low-risk preventive strategies currently exist.
Detailed Summary
Age-related cognitive decline affects a substantial portion of the aging population and represents one of the most pressing public health challenges of our time. While pharmacological interventions remain limited, dietary polyphenols — particularly those found in deeply pigmented berries — have emerged as promising candidates for supporting brain health without significant side effects.
This completed clinical trial, registered under NCT05693441 and sponsored by Aventure AB, investigated the cognitive effects of a Nordic berry beverage in adults free from diagnosed cognitive disease. The study employed both an acute protocol — measuring effects shortly after a single dose — and a chronic protocol involving 12 weeks of daily beverage consumption. A reference berry-like product served as the comparator, enabling researchers to isolate the active berry compounds' contributions.
The trial also examined whether cognitive improvements, if observed, correlated with shifts in metabolic parameters. This dual-endpoint design is significant because it attempts to link cognitive outcomes to biological mechanisms — such as changes in blood glucose regulation, inflammation, or lipid metabolism — that may mediate the brain-berry connection.
Nordic berries including bilberries, lingonberries, and cloudberries are exceptionally rich in anthocyanins and other flavonoids shown in animal and in vitro studies to cross the blood-brain barrier, reduce oxidative stress, and support cerebrovascular function. Human trial data, however, have been mixed, making this completed study a valuable contribution to the evidence base.
Results from this trial are not yet publicly detailed in the available abstract, limiting interpretation. However, the completed status suggests data have been collected and are likely undergoing or awaiting publication. If positive findings emerge, a simple dietary addition of Nordic berries could represent an accessible, low-cost strategy to support cognitive aging in otherwise healthy adults.
Key Findings
- Trial tested both acute and 12-week chronic effects of Nordic berry beverage on cognition in healthy adults.
- Metabolic biomarkers were tracked alongside cognitive outcomes to identify potential biological mechanisms.
- Study used an active berry product versus a reference berry-like comparator for controlled evaluation.
- Targets age-related cognitive decline — a condition with few proven low-risk dietary interventions.
- Trial is completed, suggesting results are forthcoming or under review for publication.
Methodology
This was a controlled clinical trial with two arms: an active Nordic berry beverage and a reference berry-like product. The design included both acute (single-dose) and chronic (12-week daily intake) assessment phases. Cognitive function and metabolic parameters were assessed across the intervention period in adults without cognitive disease.
Study Limitations
The summary is based on the abstract only, as the full trial data and results are not publicly available; no outcome data can be assessed. Sponsorship by Aventure AB, a commercial entity, warrants scrutiny for potential bias in study design or reporting. The trial's focus on cognitively healthy adults limits generalizability to those with early-stage cognitive impairment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.